Novartis AG
NVS
$164.69
$2.021.24%
NYSE
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -4.12% | -1.03% | |||
| Total Other Revenue | 16.70% | -42.58% | |||
| Total Revenue | -3.47% | -3.22% | |||
| Cost of Revenue | 0.20% | 6.51% | |||
| Gross Profit | -4.67% | -6.03% | |||
| SG&A Expenses | 4.00% | -3.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 171.43% | 1,850.00% | |||
| Total Operating Expenses | 2.37% | 4.28% | |||
| Operating Income | -15.92% | -16.09% | |||
| Income Before Tax | -23.31% | -7.39% | |||
| Income Tax Expenses | 206.02% | -47.53% | |||
| Earnings from Continuing Operations | -38.83% | -2.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 350.00% | -111.76% | |||
| Net Income | -38.67% | -2.80% | |||
| EBIT | -15.92% | -16.09% | |||
| EBITDA | -14.18% | -11.91% | |||
| EPS Basic | -38.25% | -1.68% | |||
| Normalized Basic EPS | -17.86% | -16.34% | |||
| EPS Diluted | -38.19% | -1.94% | |||
| Normalized Diluted EPS | -17.95% | -16.43% | |||
| Average Basic Shares Outstanding | -0.67% | -1.13% | |||
| Average Diluted Shares Outstanding | -0.57% | -1.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||